Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019;15(10):2359-2377.
doi: 10.1080/21645515.2019.1651140. Epub 2019 Oct 7.

Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates

John J Suschak  1 , Connie S Schmaljohn  2
Affiliations
Review

Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates

John J Suschak et al. Hum Vaccin Immunother. 2019.

Abstract

The filoviruses Ebola virus and Marburg virus are among the most dangerous pathogens in the world. Both viruses cause viral hemorrhagic fever, with case fatality rates of up to 90%. Historically, filovirus outbreaks had been relatively small, with only a few hundred cases reported. However, the recent West African Ebola virus outbreak underscored the threat that filoviruses pose. The three year-long outbreak resulted in 28,646 Ebola virus infections and 11,323 deaths. The lack of Food and Drug Administration (FDA) licensed vaccines and antiviral drugs hindered early efforts to contain the outbreak. In response, the global scientific community has spurred the advanced development of many filovirus vaccine candidates. Novel vaccine platforms, such as viral vectors and DNA vaccines, have emerged, leading to the investigation of candidate vaccines that have demonstrated protective efficacy in small animal and nonhuman primate studies. Here, we will discuss several of these vaccine platforms with a particular focus on approaches that have advanced into clinical development.

Keywords: Ebola virus; Marburg virus; filovirus; vaccines.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, Kawaoka Y, Lipkin WI, Negredo AI, Netesov SV, Nichol ST, et al. Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol. 2010;155(12):2083–103. doi:10.1007/s00705-010-0814-x. - DOI - PMC - PubMed
    1. Feldmann H, Geisbert TW.. Ebola haemorrhagic fever. Lancet. 2011;377(9768):849–62. doi:10.1016/S0140-6736(10)60667-8. - DOI - PMC - PubMed
    1. Schieffelin JS, Shaffer JG, Goba A, Gbakie M, Gire SK, Colubri A, Sealfon RSG, Kanneh L, Moigboi A, Momoh M, et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med. 2014;371(22):2092–100. doi:10.1056/NEJMoa1411680. - DOI - PMC - PubMed
    1. Team WER, Aylward B, Barboza P, Bawo L, Bertherat E, Bilivogui P, Blake I, Brennan R, Briand S, Chakauya JM, et al. Ebola virus disease in West Africa–the first 9 months of the epidemic and forward projections. N Engl J Med. 2014;371(16):1481–95. doi:10.1056/NEJMoa1411100. - DOI - PMC - PubMed
    1. WHO Ebola virus disease fact sheets. 2016. [accessed 2016 May27]. https://www.who.int/en/news-room/fact-sheets/detail/ebola-virus-disease

Publication types

Grants and funding

This work was supported by the Defense Threat and Reduction Agency [CB10204].